Journal
DRUGS
Volume 70, Issue 11, Pages 1381-1394Publisher
ADIS INT LTD
DOI: 10.2165/11537920-000000000-00000
Keywords
-
Categories
Funding
- Eisai
- Celgene
- Merck
- Bristol-Myers Squibb
- Novartis
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments have contributed significantly to advancements in the treatment of MDS: (i) improvements in classification systems and prognostic models; and (ii) the emergence of US FDA-approved agents such as lenalidomide, azacitidine and decitabine. Prior to these developments, supportive care measures consisting of blood and platelet transfusions, haematopoietic growth factors and antimicrobials remained standard of care for the treatment of MDS. As a result of these developments, clinicians are able to provide patient-tailored therapy for specific MDS subgroups. Clinical trials addressing combination therapies with multiple investigational agents as well as novel combination regimens are ongoing. This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available